Patients experience Ulcerative colitis MICROBIOTA Colorectal cancer Epigenetics Primary sclerosing cholangitis Thérapie ciblée IL23 Colorectal cancer Colibactin and lipids Colectomy Dysbiosis Cost effectiveness Anti-TNF Eligibility Therapeutics Cell adhesion MALT Cancer Intestinal crypts MORTALITY Bacteria Biologics Immune cells Crohn’s disease Heart disease risk factors COLON-CANCER Drug Clinical guidelines Clinical trial CARCINOGENESIS Inhibitor Dysbiose Colonic epithelial primary cells Disability Upper gastrointestinal tract Neoadjuvant chemotherapy Kidney diseases Survival IL12 Inclusion DNA METHYLATION Small molecules Disease Progression Helicobacter pylori Maintenance therapy Surgery Tailored therapy Vedolizumab Biomarker Inflammatory Bowel Diseases Monitoring Colon cancer Epigénétiques Disease progression Eradication Crohn's disease Effectiveness Bactéries Parvimonas micra Acceptability Resistance Genes DNA methylation Colon Algorithm Tuberculosis Méthylation HIV Patient-reported outcome Stricture Ustekinumab Fecal microbiota Venous thromboembolism PCR Safety Microbiote Gènes Gene methylation 18 FDG-PET/CT Inflammatory bowel diseases T1118 translocation Consensus Microbiota RISK Rituximab plus chlorambucil Original Article Clinical Alkylating agents Contraindication Anti-TNF agents Inflammatory bowel disease IBD Endoscopic treatment Rituximab Methylation Over 80s MARKER Résistance Gene expression Screening Immunosuppressant